FDA 483 - Pharmacy Specialists of Central Florida, Inc. dba Pharmacy Specialists - June 08, 2017

This FDA Form 483 document details observations made during an inspection, indicating deficiencies in the firm's operations.

**Observation 1:** The firm failed to establish an adequate quality control unit. This suggests a systemic issue with the oversight and management of quality-related activities, which is a fundamental requirement for ensuring product quality and compliance.

**Observation 2:** The firm did not adequately validate the cleaning processes for manufacturing equipment. This is a critical finding as inadequate cleaning validation can lead to cross-contamination of products, potentially affecting product purity, safety, and efficacy. Proper validation ensures that cleaning procedures consistently remove residues to acceptable levels.

**Observation 3:** The firm did not maintain proper records of batch production and control. This indicates a failure in documentation practices, which are essential for traceability, quality assurance, and regulatory compliance. Inadequate records can hinder investigations into product quality issues and demonstrate a lack of control over manufacturing processes.

Collectively, these observations point to significant deficiencies in the firm's quality system, manufacturing controls, and record-keeping practices. These issues have substantial business and operational implications, potentially leading to regulatory actions, product recalls, and damage to the firm's reputation. Addressing these observations requires comprehensive corrective actions to bring the facility into compliance with regulatory requirements.